Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Medulloblastoma 1Ependymoma 1

Interventions

Temozolomide 4Watchful Waiting 2Vincristine 2Filgrastim 2Etoposide 2Cyclophosphamide 2Cisplatin 2veliparib 1omburtamab I-131 1lonafarnib 1imetelstat 1Triiodothyronine 1Radiotherapy, Conformal 1Radiotherapy 1Potassium Iodide 1Platinum 1Observation 1Mesna 1Irinotecan 1Histamine Antagonists 1Granulocyte Colony-Stimulating Factor 1GRN163L peptide 1Dexamethasone 1Chemotherapy, Adjuvant 1Carboplatin 1Bevacizumab 1Antipyretics 1Antiemetics 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Ependymoma × Histamine Antagonists × Clear all
NCT04743661 2026-02-05

131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma

Pediatric Brain Tumor Consortium

Phase 2 Active not recruiting
62 enrolled
CNS

Ependymoma, Medulloblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡